Archives of Toxicology

, Volume 88, Issue 4, pp 901–911

Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients

  • Victor C. Lin
  • Chao-Yuan Huang
  • Yung-Chin Lee
  • Chia-Cheng Yu
  • Ta-Yuan Chang
  • Te-Ling Lu
  • Shu-Pin Huang
  • Bo-Ying Bao

DOI: 10.1007/s00204-014-1196-8

Cite this article as:
Lin, V.C., Huang, CY., Lee, YC. et al. Arch Toxicol (2014) 88: 901. doi:10.1007/s00204-014-1196-8


Since the tumor protein p53 (TP53), a transcription factor, plays a crucial role in prostate cancer development and progression, we hypothesized that sequence variants in TP53 binding sites might affect clinical outcomes in patients with prostate cancer. We systematically evaluated 41 single nucleotide polymorphisms (SNPs) within genome-wide predicted TP53 binding sites in a cohort of 1,024 prostate cancer patients. The associations of these SNPs with prostate cancer characteristics and clinical outcomes after radical prostatectomy for localized disease and after androgen-deprivation therapy (ADT) for advanced disease were assessed by Kaplan–Meier analysis and Cox regression model. ARAP2 rs1444377 and TRPS1 rs722740 were associated with advanced stage prostate cancer. FRK rs171866 remained as a significant predictor for disease progression; DAB2 rs268091 and EXOC4 rs1149558 remained as significant predictors for prostate cancer-specific mortality (PCSM); and EXOC4 rs1149558 remained as a significant predictor for all-cause mortality after ADT in multivariate models that included clinicopathologic predictors. In addition, the numbers of protective genotypes at DAB2 rs268091 and EXOC4 rs1149558 showed a cumulative effect on PCSM (P for trend = 0.002). Our results suggested that SNPs within TP53 binding sites might be valuable biomarkers for prostate cancer outcome prediction.


Mortality Prognosis Prostate cancer Single nucleotide polymorphism (SNP) TP53 Transcription factor binding sites 



Single nucleotide polymorphism


Radical prostatectomy


Androgen-deprivation therapy


Prostate cancer-specific mortality


All-cause mortality


Prostate-specific antigen


Odds ratio

95 % CI

95 % confidence interval


Hazard ratio

Supplementary material

204_2014_1196_MOESM1_ESM.doc (232 kb)
Supplementary material 1 (DOC 231 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Victor C. Lin
    • 1
    • 2
  • Chao-Yuan Huang
    • 3
  • Yung-Chin Lee
    • 4
    • 5
  • Chia-Cheng Yu
    • 6
    • 7
    • 8
  • Ta-Yuan Chang
    • 9
  • Te-Ling Lu
    • 10
  • Shu-Pin Huang
    • 4
    • 5
  • Bo-Ying Bao
    • 10
    • 11
  1. 1.Department of UrologyE-Da HospitalKaohsiungTaiwan
  2. 2.Department of NursingI-Shou UniversityKaohsiungTaiwan
  3. 3.Department of Urology, National Taiwan University Hospital, College of MedicineNational Taiwan UniversityTaipeiTaiwan
  4. 4.Department of UrologyKaohsiung Medical University HospitalKaohsiungTaiwan
  5. 5.Department of Urology, Faculty of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  6. 6.Division of Urology, Department of SurgeryKaohsiung Veterans General HospitalKaohsiungTaiwan
  7. 7.Department of Urology, School of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  8. 8.Department of PharmacyTajen UniversityPingtungTaiwan
  9. 9.Department of Occupational Safety and HealthChina Medical UniversityTaichungTaiwan
  10. 10.Department of PharmacyChina Medical UniversityTaichungTaiwan
  11. 11.Sex Hormone Research CenterChina Medical University HospitalTaichungTaiwan

Personalised recommendations